Plus Therapeutics

CEO & President, Dr. Marc Hedrick, dives into the importance of targeted radiotherapeutics in treating CNS cancers in this Life Science Daily News article.

Read more: https://lifesciencedaily.news/targeted-radiotherapeutics-cns-cancers/

Targeted Radiotherapeutics | Life Science Daily News Targeted radiotherapeutics deliver radiation directly to CNS tumours, improving efficacy and reducing damage to healthy tissue.

CNSide Diagnostics' President and General Manager, Russell Bradley, exhibited at Best of American Society of Clinical Oncology in Austin, Texas this weekend, focused on raising awareness for (LM)

is a serious and often under-recognized complication of advanced cancer that occurs when cancer spreads to the membranes surrounding the brain and spinal cord, underscoring the need for greater awareness and education within the oncology community.

At the meeting, he highlighted how the CNSide® platform is helping advance the diagnosis and management of LM through innovative cerebrospinal fluid (CSF) analysis designed to support more informed clinical decision-making.

Learn more about : cnside-dx.com

' President and CEO, Dr. Marc Hedrick, recently joined the Rare Connection podcast to discuss emerging approaches to diagnosing and treating cancers affecting the central nervous system, including (LM), recurrent ( ), and pediatric brain cancers.

Dr. Hedrick also covers the CNSide Diagnostics' platform, how cerebrospinal fluid is analyzed to identify cancer cells, and how targeted are being investigated in ongoing .

Check out the podcast here:

Targeting Brain Tumors: The New Radiotherapeutic Trial You Need to Know What happens when cancer spreads to the fluid surrounding the brain...

Today is , a moment to raise awareness for those living with brain tumors, their caregivers, and the advocates driving awareness and research forward.

' is committed to developing innovative approaches that aim to address some of the most challenging cancers of the central nervous system.

Learn more about our brain cancer clinical trials: https://bit.ly/4e0ulJG

National Brain Tumor Society American Brain Tumor Association

Today is National Cancer Survivors Day, a moment to recognize cancer survivors, inspire those recently diagnosed, and to bring awareness and support to affected families.

The team stands with survivors and current patients as we all work together to end cancer.

announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program, recognized as the “gold standard” in laboratory accreditation.

As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, safety programs, and overall laboratory management. now joins more than 8,000 CAP-accredited laboratories worldwide.

Full press release here: bit.ly/4o5d4Um

CNSide Diagnostics is exhibiting at Best of American Society of Clinical Oncology in Austin, Texas later this month. This event is a a free opportunity designed for clinicians, researchers, and allied health professionals seeking the latest updates in cancer care.

If you are attending, we invite you to stop by the booth to connect with our team and learn how our diagnostic platform supports precision .

Read more about the event and register: https://bit.ly/3QjzxAD

As comes to a close, our Plus Therapeutics and CNSide Diagnostics teams wore gray to honor brain cancer patients, their caregivers, advocates, and fellow researchers who work together every day to develop new diagnostics and treatments.

National Brain Tumor Society American Brain Tumor Association

announces the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of LM using the CNSide cerebrospinal fluid assay.

The company believes that this cost-of-care analysis underscores that earlier LM diagnosis and therapeutic management enabled by reduces overall LM-related healthcare costs by approximately 40%. These savings are driven by earlier therapeutic intervention, improved treatment precision, and reduced hospitalizations.

The data were presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research 2026 Annual Meeting, where it was rewarded the Blue Ribbon Award as a top 5% presentation.

Full press release here: https://bit.ly/3RvFBGy

Link to poster: https://bit.ly/4uxKD45

About CNSide: https://bit.ly/49oPcoK

The and CNSide Diagnostics teams will be at the American Society of Clinical Oncology Annual Meeting, beginning at the end of next week.

Email us at [email protected] or [email protected] to schedule an onsite meeting.